Patents by Inventor Michel Chretien
Michel Chretien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210161933Abstract: A kit for reducing the risk of filovirus hemorrhagic fever or a symptom thereof in a mammal host exposed to a filovirus (e.g., Ebola or Zika virus), comprising an effective amount of quercetin-3?-O-D-glucoside (Q3G) or an analogue thereof, or a composition comprising Q3G or analogue thereof and a pharmaceutically acceptable carrier.Type: ApplicationFiled: January 26, 2021Publication date: June 3, 2021Inventors: Michel CHRÉTIEN, Majambu MBIKAY, Xiangguo QIU
-
Patent number: 10987371Abstract: A method of reducing the risk of filovirus hemorrhagic fever or a symptom thereof in a mammal host exposed to a filovirus (e.g., Ebola or Zika virus), comprising administering an effective amount of quercetin-3 ?-O-D-glucoside (Q3G) or an analogue thereof, or a composition comprising Q3G or analogue thereof and a pharmaceutically acceptable carrier, to said host prior to said exposure.Type: GrantFiled: June 7, 2018Date of Patent: April 27, 2021Inventors: Michel Chrétien, Majambu Mbikay, Xiangguo Qiu
-
Publication number: 20180353528Abstract: A method of reducing the risk of filovirus hemorrhagic fever or a symptom thereof in a mammal host exposed to a filovirus (e.g., Ebola or Zika virus), comprising administering an effective amount of quercetin-3 ?-O-D-glucoside (Q3G) or an analogue thereof, or a composition comprising Q3G or analogue thereof and a pharmaceutically acceptable carrier, to said host prior to said exposure.Type: ApplicationFiled: June 7, 2018Publication date: December 13, 2018Inventors: MICHEL CHRÉTIEN, MAJAMBU MBIKAY, XIANGGUO QIU
-
Publication number: 20150190369Abstract: There is described herein a use of quercetin-3-O-?-D-glucoside (Q3G) for increasing the amount of cell surface low-density lipoprotein receptor (LDLR) on a cell and for reducing the amount of functional proprotein convertase subtilisin/kexin type 9 (PCSK9) secreted by the cell, where the Q3G is formulated for administration to the cell, and where the increase in cell surface LDLR and the decrease in secretion of functional PCSK9 is in comparison to the cell not exposed to Q3G. The use may optionally include the treatment of a statin. There is also described a method of reducing plasma cholesterol levels in a patient in need thereof. The method includes treating the patient with a therapeutically effective amount of Q3G and, optionally, a therapeutically effective amount of a statin.Type: ApplicationFiled: June 28, 2013Publication date: July 9, 2015Inventors: Majambu Mbikay, Francine Sirois, Michel Chretien, Janice Mayne
-
Patent number: 7928189Abstract: The present invention provide PCSK9 polypeptides, fragments thereof and methods of modulating PCSK9 phosphorylation and low density lipoprotein degradation.Type: GrantFiled: May 5, 2008Date of Patent: April 19, 2011Assignee: Ottawa Health Research InstituteInventors: Janice Mayne, Michel Chrétien, Majambu Mbikay
-
Patent number: 7900964Abstract: A section of a motor vehicle front low area includes a first extendable elongated part, whose rear end is placed in front of a vehicle structural element embodied in a form of a cradle, whereas the front end thereof is connected to a bar-type structural element of the vehicle by a first connection device. The rear end of the first elongated part is movably mounted in front of the cradle-shaped vehicle structural element. The first connection device includes a connection in a form of a slide bar enabling a substantially longitudinal movement to be carried out and a removable stop member for normally hindering movement up to the removal.Type: GrantFiled: June 6, 2006Date of Patent: March 8, 2011Assignee: ArcelorMittal Tubular Products VitryInventors: Jean-Michel Chretien, Arnaud Cocu, Jean-Louis Colmont, Thierry Derchu
-
Publication number: 20100201159Abstract: A section of a motor vehicle front low area includes a first extendable elongated part, whose rear end is placed in front of a vehicle structural element embodied in a form of a cradle, whereas the front end thereof is connected to a bar-type structural element of the vehicle by a first connection device. The rear end of the first elongated part is movably mounted in front of the cradle-shaped vehicle structural element. The first connection device includes a connection in a form of a slide bar enabling a substantially longitudinal movement to be carried out and a removable stop member for normally hindering movement up to the removal.Type: ApplicationFiled: June 6, 2006Publication date: August 12, 2010Applicant: Vallourec Composants Automobiles VitryInventors: Jean-Michel Chretien, Arnaud Cocu, Jean-Louis Colmont, Thierry Derchu
-
Publication number: 20090275504Abstract: The present invention provide PCSK9 polypeptides, fragments thereof and methods of modulating PCSK9 phosphorylation and low density lipoprotein degradation.Type: ApplicationFiled: May 5, 2008Publication date: November 5, 2009Inventors: Janice Mayne, Michel Chretien, Majambu Mbikay
-
Mammalian Subtilisin/kexin isozyme SKI-1: a proprotein convertase with a unique cleavage specificity
Patent number: 7211424Abstract: Using RT-PCR and degenerate oligonucleotides derived from the active site residues of subtilisin-kexin-like serine proteinases, we have identified a highly conserved and phylogenetically ancestral human, rat and mouse type-I membrane-bound proteinase called subtilisin-kexin-isozyme-1 (SKI-1). Computer data bank searches reveals that human SKI-1 was previously cloned but with no identified function. A SKI-1 processed fragment is secreted in culture media in a soluble form. In vitro studies suggest that SKI-1 is a Ca2+-dependent serine proteinase exhibiting a wide pH optimum for cleavage of proBDNF. Peptides mimicking SKI-1 cleavages sites are also disclosed. SKI-1 prosegment has an ex vivo inhibitory effect on SKI-1 activity. The prosegment is also processed and secreted in culture media. One of its fragments is found tightly associated with the SKI-1 soluble form. Therapeutic applications for SKI-1 inhibitors are disclosed.Type: GrantFiled: November 4, 1999Date of Patent: May 1, 2007Assignee: Institut de Recherches Cliniques de MontrealInventors: Nabil G. Seidah, Michel Chretien, Mieczyslaw Marcinkiewicz -
Publication number: 20040180417Abstract: A novel Asp-ase activity, referred to as BACE secretase/sheddase, has been found to cleave the ectoddomain of BACE after Asp379 (SQDD↓) and Asp407 (VVFD↓), and likely after Asp451 (PQTD↓). The cleavage of BACE by BACE secretase/sheddase renders BACE soluble which in turns appears to enhance the generation of the amyloidogenic peptide A&bgr;, which has been implicated as a major factor in the etiology of Alzheimer's Disease. The current invention concerns the modulation of this novel BACE secretase/sheddase activity for such applications as the prevention or treatment of a neurodegenerative disorder that is characterized by the generation of A&bgr; protein, including Alzheimer's Disease.Type: ApplicationFiled: April 5, 2004Publication date: September 16, 2004Inventors: Nabil G. Seidah, Michel Chretien, James A. Cromish
-
Patent number: 6380171Abstract: The present invention relates to the cloning of human pro-protein converting enzyme 5 (PC5) CDNA isolated from human adrenal gland messenger RNA. Additionally, this invention relates to a method for reducing restenosis occurring at an injured vascular site comprising delivering to the injured site an antisense nucleic acid to suppress the expression of human PC5.Type: GrantFiled: September 13, 1999Date of Patent: April 30, 2002Assignees: Clinical Research Institute of Montreal, Universite de Montreal, Centre hospitalier de l'Universite de MontrealInventors: Robert Day, Nabil G. Seidah, Rémi Martel, Michel Chrétien, Tim Reudelhuber, Guy LeClerc
-
Patent number: 5840529Abstract: This invention relates to a novel and seventh member of the subtilisin-kexin family isolated from rat, which has been named rPC7. The rat spleen cDNA has been totally sequenced. A shorter DNA sequence has been obtained for human, which corresponds to a portion of the catalytic region of a human pro-hormone convertase corresponding to the rat pro-hormone convertase. PC7 clearly distinguishes from the other mammalian members of the subtilisin-kexin family. Its tissue distribution is ubiquitous, but its presence is particularly remarkable in lymphoid tissues. It is present in LoVo cells that are able to cleave the HIV gp160 protein into active gp120/gp41 proteins and that are deficient in other effective pro-hormone convertases known up to date. Therefore, it is proposed that PC7 is a good candidate as a maturation enzyme responsible for the conversion of HIV gp160 protein in target CD.sup.+4 cells.Type: GrantFiled: October 19, 1995Date of Patent: November 24, 1998Assignee: Clinical Research Institute of MontrealInventors: Nabil G. Seidah, Robert Day, Michel Chretien
-
Patent number: 5789564Abstract: The present invention relates to pro-hormone convertases and polypeptidic fragments thereof, nucleic acids encoding them, recombinant viruses expressing these convertases, polyclonal antibodies directed against the convertases, diagnostic kits for the detection and measurement of the convertase content in cell or tissue lysates, culture media or biological fluids by RIA. Diagnostic kits were also developped for detection or measurement of nucleic acids, preferably mRNAs, in cell or tissue lysates by hybridization. The invention also concerns oligonucleotides useful as probes or as primers for DNA synthesis. These oligonucleotides were included in the diagnostic kits as well as used for the obtention of specific fragments of the convertases which have served, together with native convertases, as antigens for the obtention of antibodies. The convertases were produced by mammalian cell lines transfected with the recombinant viruses and purified on affinity columns which are also an object of the invention.Type: GrantFiled: September 12, 1996Date of Patent: August 4, 1998Assignee: Institut de Recherches Cliniques de MontrealInventors: Nabil G. Seidah, Michel Chretien
-
Patent number: 4632780Abstract: There are disclosed the N-terminal fragment of human pro-opiomelanocortin, a glycopeptide composed of 76 amino acid residues, and a process for preparing same from human pituitary glands. The glycopeptide is useful in potentiating the effects of ACTH on steroidogenesis, in stimulating the production of aldosterone, as a diagnostic tool, as well as a reagent for determining its presence in biological fluids and tissues by immunochemical means.Type: GrantFiled: July 10, 1981Date of Patent: December 30, 1986Inventors: Nabil G. Seidah, Michel Chretien
-
Patent number: 4607023Abstract: Novel peptides in substantially pure form and selected from the group of peptides having the amino acid sequence:X-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Y-ZwhereinY is selected from the group consisting of -Asn, -Asn-Ser, -Asn-Ser-Phe, -Asn-Ser-Phe-Arg, and -Asn-Ser-Phe-Arg-Tyr;Z is OH or NH.sub.2 ; andX is selected from the group consisting of H, Ser-, Ser-Ser-, Arg-Ser-Ser-, Arg-Arg-Ser-Ser-, Leu-Arg-Arg-Ser-Ser, Ser-Leu-Arg-Arg-Ser-Ser-, Arg-Ser-Leu-Arg-Arg-Ser-Ser-, Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser-, Gly-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser, Ala-Gly-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser-, Leu-Ala-Gly-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser, and Glu-Val-Pro-Trp-Thr-Gly-Glu-Val-Asn-Pro-Ser-Gln-Arg-Asp-Gly-Gly-Ala-Leu-Gl y-Arg-Gly-Pro-Trp-Asp-Pro-Ser-Asp-Arg-Ser-Ala-Leu-Lys-Ser-Lys-Leu-Arg-Ala-L eu-Leu-Ala-Gly-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser-,are disclosed as having diuretic, natriuretic, vasorelaxant, hypotensive or anti-hypertensive properties.Type: GrantFiled: August 27, 1984Date of Patent: August 19, 1986Assignee: L'Institut de Recherches Cliniques de MontrealInventors: Gaetan Thibault, Raul Garcia, Marc Cantin, Nabil Seidah, Claude Lazure, Michel Chretien